Blip

About this episode

Spherix Incorporated (NASDAQ CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive interim Phase 3 clinical results for the planned review of the NEET (Naturlose (D-tagatose) Efficacy Evaluation Trial) trial of D-tagatose in drug naïve patients. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/spherix/40911/

• Release Date

  Nov 16, 2009

• Runtime

  02:23